Company Overview of EOS (Ethical Oncology Science) S.p.A.
EOS (Ethical Oncology Science) S.p.A. develops targeted medicines to treat cancer. It is primarily involved in the development of Lucitanib, an oral small-molecule tyrosine kinase inhibitor that is in Phase I/II development to prevent the development of new blood vessels essential for tumor growth and to interfere with tumor growth in certain FGF-dependent malignancies. The company was founded in 2006 and is based in Milan, Italy. As of November 19, 2013, EOS (Ethical Oncology Science) S.p.A. operates as a subsidiary of Clovis Oncology, Inc.
Via Monte di Pietà n.1/A
Milan, MI 20121
Founded in 2006
39 02 87 39 16 08
39 02 87 39 16 17
Key Executives for EOS (Ethical Oncology Science) S.p.A.
Similar Private Companies By Industry
|Arterra Bioscience s.r.l.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact EOS (Ethical Oncology Science) S.p.A., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.